

CASE STUDY

Scaling Individualized Patient Care at Indiana University Health



Indiana University Health uses **LifeOmic Oncology** to reduce their time interpreting each patient's genetic data by over 60%. This allows the precision genomics team to focus on delivering care to more patients than ever before.

The Problem

Large-scale studies in cancer genomics have demonstrated that while there are shared drivers between different tumors, each patient's cancer is quite unique. **Therapy needs to be tailored to each patient's unique cancer and genetics** which takes time and careful review of large amounts of data. Dr. Milan Radovich, VP for Oncology Genomics at Indiana University Health wanted to combat the amount of time spent per patient reviewing their case and find alternative therapies quickly for complicated cases.

The Solution

LifeOmic Oncology accelerates oncology analysis by bringing all relevant patient information from clinical records to genomic sequencing into one platform for quick interpretation.



Subject Viewer

LifeOmic Oncology's subject viewer capabilities provided Indiana University Health with a configurable view of their patients' longitudinal history, combining clinical and genomic data to better facilitate a treatment plan at scale.



Omics Explorer

The Omics Explorer capability contains an updated knowledge base with oncological variant data and clinical relevant drug information that allowed the precision genomics team to easily import sequencing reports and query for known details around variants, genes or genomic regions of interest.



The Outcome



60%

reduction in time to interpret each patient's genetic data

Increased Time Savings and Patient Throughput

With LifeOmic Oncology and the power of disparate data sources coming together, Dr. Milan Radovich and his team reduced the time needed to interpret each patient by over 60% reducing the total time from 15-30 minutes to 5 minutes. This enabled the program to quickly scale precision medicine efforts to more patients.

Improved Patient Outcomes

In one interesting case, the platform helped identify a rare genomic mutation as the solitary driver for a Metastatic Cholangiocarcinoma. This allowed the precision genomics team at Indiana University Health and his oncologist to identify a drug treatment specific to the rare genomic alteration. The patient has a dramatic response therapy that has been sustained.



66

The LifeOmic Oncology platform was crucial because "given the continual flow of new evidence associating genomic alterations with potential therapies, having an informatics platform [like LifeOmic Oncology] ensures that no stone is unturned in the search for a tailored therapy or a clinical trial. Having a tool to lean on for oncologists is vital to better provide the right drug to the right patient at the right time."

> Milan Radovich, PhD Former VP for Oncology Genomics, Indiana University Health